Zymeworks (ZYME) News
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.14-0.72 (-2.68%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZYME news summary
We found 12 recent headlines mentioning Zymeworks (ZYME): 4 in the past week and 7 in the past 30 days, most often from GlobeNewswire, Seeking Alpha, Investing.com. For price context, ZYME is down 2.68% at $26.14. The most recent story, "Zymeworks Announces Participation in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Zymeworks headlines
- Zymeworks Announces Participation in Upcoming Investor ConferencesVANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…GlobeNewswire
- Zymeworks Authorized To Buy Back Up To $200 Mln Of Shares(RTTNews) - Zymeworks Inc. (ZYME), a biotechnology company, said Monday that its Board has authorized a second share repurchase program of up to $200 million, which is expected to begin before the…Nasdaq
- Zymeworks authorizes up to $200M in share repurchasesSeeking Alpha
- Zymeworks Announces $200 Million Share Repurchase AuthorizationVANCOUVER, British Columbia, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…GlobeNewswire
- Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsVANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse…GlobeNewswire
- Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancerSeeking Alpha
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…GlobeNewswire
- Why is Zymeworks stock surging today?Investing.com
- Zymeworks stock surges on $813M Roche licensing dealInvesting.com
- Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…GlobeNewswire
- Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance BiopharmaVANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…GlobeNewswire
- Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsZymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026GlobeNewswire